Glomerulonephritis Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Asserts DelveInsight | AstraZeneca, Alnylam, Apellis, Otsuka, Visterra, ChemoCentryx, Omeros

Glomerulonephritis Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) -  Asserts DelveInsight | AstraZeneca, Alnylam, Apellis, Otsuka, Visterra, ChemoCentryx, Omeros
Delveinsight Business Research LLP
As per DelveInsight, the Glomerulonephritis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Glomerulonephritis and the improvement in the research and development activities so that the market will comprise efficient treatment options.

DelveInsight’s “Glomerulonephritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Glomerulonephritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Glomerulonephritis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Glomerulonephritis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Glomerulonephritis: An Overview

Glomerulonephritis (GN) also known as nephritis or nephrotic syndrome is a group of diseases that injure the part of the kidney that filters blood (called glomeruli). When the kidney is injured, it cannot get rid of wastes and extra fluid in the body. If the illness continues, the kidneys may stop working completely, resulting in kidney failure.

There are two types of Glomerulonephritis —acute and chronic. The acute form develops suddenly. The chronic form may develop silently (without symptoms) over several years. It often leads to complete kidney failure. It can aslo be classified as originating in or confined primarily to the kidney (primary) and as related to systemic immunologic disorders, such as systemic lupus erythematosus (SLE) (secondary).

The acute disease may be caused by infections such as strep throat. It may also be caused by other illnesses, including lupus, Goodpasture’s syndrome, Wegener’s disease, and polyarteritis nodosa. Sometimes, the disease runs in the family. This kind often shows up in young men who may also have hearing loss and vision loss. Some forms are caused by changes in the immune system. However, in many cases, the cause is not known.

Glomerulonephritis often comes to light when a routine urinalysis is abnormal. Tests to assess kidney function and make a diagnosis of Glomerulonephritis include urine tests, blood tests, imaging tests, and kidney biopsies. The treatment for glomerulonephritis depends on what is causing it. Certain medicines called angiotensin-converting enzyme (ACE) inhibitors such as captopril, lisinopril, perindopril, and angiotensin receptor blockers (ARBs) such as losartan, irbesartan, valsartan can help control blood pressure.  

Though there are no FDA-approved drugs for the treatment of Glomerulonephritis but many different therapies have been studied for the cure of its separate clinical features.

Glomerulonephritis Market Key Facts

  • lso, Vendemia et al. conducted a study where a report from the Italian Registry of Renal Biopsy where elderly patients accounted for approximately 19% of those of biopsy-proven primary Glomerulonephritis, and elderly people were only 16% of the Italian population. This disproportion indicated that the occurrence of primary Glomerulonephritis in the elderly was higher than expected: actually, when compared to the occurrence in the adults, it was 30.8 vs. 28.3 cases per million of the population (PMP). 

  • Kazi et al. (2020) conducted a study titled “Glomerulonephritis”, which stated that Glomerulonephritis is a prominent cause of renal impairment. It leads to 10 to 15% of end-stage renal disease cases in the US. In most instances, without timely intervention, the disease becomes progressive, eventually leading to morbidity. This makes chronic glomerulonephritis the third most common cause of end-stage renal disease in the US following diabetes mellitus and hypertension, accounting for 10% of patients on dialysis.

  • In US children and adolescents younger than 18 years, polycystic kidney disease and glomerulonephritis (inflammation of the kidneys) are the main causes of end-stage kidney disease (ESKD).

  • The pipeline of Glomerulonephritis (GN) possesses several mid-phase potential key players, such as AstraZeneca, Novartis Pharmaceuticals, Alnylam Pharmaceuticals, Apellis Pharmaceuticals, Otsuka, and Omeros Corporation


Glomerulonephritis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Glomerulonephritis pipeline therapies. It also thoroughly assesses the Glomerulonephritis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Glomerulonephritis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Glomerulonephritis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Glomerulonephritis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Glomerulonephritis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Glomerulonephritis Epidemiology, Segmented as –

  • Prevalent Population of Glomerulonephritis in the 7MM 

  • Diagnosed Prevalent Population of Glomerulonephritis in the 7MM 

  • Gender-specific Prevalent Population of Glomerulonephritis in the 7MM 

  • Treatable Cases of Glomerulonephritis in the 7MM 

Glomerulonephritis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Glomerulonephritis market or expected to be launched during the study period. The analysis covers the Glomerulonephritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Glomerulonephritis drugs based on their sale and market share.

The report also covers the Glomerulonephritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Glomerulonephritis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Glomerulonephritis Market Will Evolve and Grow by 2032 @

Glomerulonephritis Therapeutics Analysis

Treatment of Glomerulonephritis depends on the form of the disease, underlying cause, type, and severity of signs and symptoms. For example, if high blood pressure causes damage to glomeruli, treatment will likely focus on controlling the blood pressure. Certain medicines called angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) can help control blood pressure. Antibiotic therapy to prevent streptococcal infection ( Prophylaxis ), steroids to suppress immunity, high calories and Low protein, sodium & potassium diet, and monitoring for signs of kidney failure, heart failure, and hypertensive encephalopathy are the treatments for Glomerulonephritis.

To further improve the treatment outlook, several major pharma and biotech companies are actively working in the Glomerulonephritis therapeutics market. Several of the therapies are in the advanced stages of clinical development, expected to enter the market in the near future. 

Glomerulonephritis Companies Actively Working in the Therapeutics Market Include

  • AstraZeneca

  • Novartis Pharmaceuticals

  • Alnylam Pharmaceuticals

  • Apellis Pharmaceuticals

  • Otsuka 

  • Visterra

  • ChemoCentryx

  • Omeros Corporation

And Many Others

Emerging and Marketed Glomerulonephritis Therapies Covered in the Report Include:

  • AZD2373: AstraZeneca

  • LNPO23: Novartis Pharmaceuticals

  • Cemdisiran: Alnylam Pharmaceuticals

  • APL-2: Apellis Pharmaceuticals

  • VIS649: Visterra

  • Avacopan : ChemoCentryx

  • OMS721: Omeros Corporation

And Many More

The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Glomerulonephritis Competitive Intelligence Analysis

4. Glomerulonephritis Market Overview at a Glance

5. Glomerulonephritis Disease Background and Overview

6. Glomerulonephritis Patient Journey

7. Glomerulonephritis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Glomerulonephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Glomerulonephritis Unmet Needs

10. Key Endpoints of Glomerulonephritis Treatment

11. Glomerulonephritis Marketed Therapies

12. Glomerulonephritis Emerging Drugs and Latest Therapeutic Advances

13. Glomerulonephritis Seven Major Market Analysis

14. Attribute Analysis

15. Glomerulonephritis Market Outlook (In US, EU5, and Japan)

16. Glomerulonephritis Companies Active in the Market

17. Glomerulonephritis Access and Reimbursement Overview

18. KOL Views on the Glomerulonephritis Market

19. Glomerulonephritis Market Drivers

20. Glomerulonephritis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Indolent Lymphoma Market

“Indolent Lymphoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Indolent Lymphoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Indolent Lymphoma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States